Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2016
New Zealand Pharmaceutical Schedule - 1 September 2016 update
1 September 2016 - The September 2016 issue of the New Zealand Pharmaceutical Schedule sees the listing of one new ...
Posted by Michael Wonder on 30 Aug 2016
Decision to award sole supply to Zoladex and reference price Eligard and Lucrin
30 August 2016 - PHARMAC has made decisions to award the Zoladex brand of goserelin acetate sole subsidised supply in the ...
Posted by Michael Wonder on 28 Aug 2016
Cancer campaigner and melanoma patient Jeffrey Paterson dies aged 23
28 August 2016 - Young melanoma patient Jeffrey Paterson helped to win the campaign for Government funding of Keytruda, but didn't ...
Posted by Michael Wonder on 21 Aug 2016
The impact of innovative pharmaceuticals on New Zealand cancer patients
22 August 2016 - Medicines New Zealand is hosting an educational seminar in Wellington on Wednesday 24 August with University of ...
Posted by Michael Wonder on 21 Aug 2016
Economist visits New Zealand to present ground-breaking cancer research
22 August 2016 - Renowned American economist, Professor Frank Lichtenberg, has been commissioned by Medicines New Zealand to analyse the impact ...
Posted by Michael Wonder on 18 Aug 2016
Subsidised access to new melanoma drugs: in need of further innovation?
19 August 2016 - New Zealand is now the melanoma capital of the world but is behind the rest of ...
Posted by Michael Wonder on 18 Aug 2016
PHARMAC calls on Tauranga for advice
18 August 2016 - PHARMAC is asking Tauranga people to help it make some changes to how it should best distribute ...
Posted by Michael Wonder on 17 Aug 2016
Reform PHARMAC or people will die, melanoma survivor tells MPs
17 August 2016 - Leisa Renwick planned to spend Mother's Day last year with her family but ended up in Tauranga ...
Posted by Michael Wonder on 10 Aug 2016
Proposal to award sole supply of venlafaxine hydrochloride
10 August 2016 - PHARMAC is seeking feedback on a proposal to award sole supply status in the community for venlafaxine hydrochloride ...
Posted by Michael Wonder on 09 Aug 2016
Proposal to award sole supply of leflunomide
9 August 2016 - PHARMAC is seeking feedback on a proposal to award Sole Supply Status in the community for leflunomide to ...
Posted by Michael Wonder on 08 Aug 2016
Decision relating to enoxaparin sodium and plerixafor
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis New Zealand Limited (Sanofi) for ...
Posted by Michael Wonder on 08 Aug 2016
Decision relating to idarucizumab and dabigatran
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Boehringer Ingelheim NZ Limited for the ...
Posted by Michael Wonder on 04 Aug 2016
PHARMAC updates its funding applications list
3 August 2016 - PHARMAC has published the funding applications received for PTAC for 2016. ...
Posted by Michael Wonder on 02 Aug 2016
Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
2 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe and Dohme (New Zealand) ...
Posted by Michael Wonder on 31 Jul 2016
New Zealand Pharmaceutical Schedule - 1 August 2016 update
1 August 2016 - The August 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...